The addition of progesterone to hormone replacement therapy (HRT) has been found to raise the risk of breast cancer. It is worth noting that taking low doses of progesterone alone, without oestrogen, does not seem to have the same effect on breast cancer risk. If used for less than 10 years, oestrogen-only HRT does not appear to increase the likelihood of developing breast cancer. However, it does increase the risk of endometrial cancer and should be avoided unless the patient has had a hysterectomy.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

Based on the given history, it appears that there is a blockage preventing the normal flow of menstrual blood. This is indicated by the presence of secondary sexual characteristics and recurring abdominal pain. It can be ruled out that the cause of this condition is a bicornuate uterus, dermoid cysts, endometriosis, or pelvic inflammatory disease, as these are not associated with primary amenorrhoea.

Understanding Amenorrhoea: Causes, Investigations, and Management

Amenorrhoea is a condition characterized by the absence of menstrual periods in women. It can be classified into two types: primary and secondary. Primary amenorrhoea occurs when menstruation fails to start by the age of 15 in girls with normal secondary sexual characteristics or by the age of 13 in girls without secondary sexual characteristics. On the other hand, secondary amenorrhoea is the cessation of menstruation for 3-6 months in women with previously normal and regular menses or 6-12 months in women with previous oligomenorrhoea.

There are various causes of amenorrhoea, including gonadal dysgenesis, testicular feminization, congenital malformations of the genital tract, functional hypothalamic amenorrhoea, congenital adrenal hyperplasia, imperforate hymen, hypothalamic amenorrhoea, polycystic ovarian syndrome, hyperprolactinemia, premature ovarian failure, Sheehan’s syndrome, Asherman’s syndrome, and thyrotoxicosis. To determine the underlying cause of amenorrhoea, initial investigations such as full blood count, urea & electrolytes, coeliac screen, thyroid function tests, gonadotrophins, prolactin, and androgen levels are necessary.

The management of amenorrhoea depends on the underlying cause. For primary amenorrhoea, it is important to investigate and treat any underlying cause. Women with primary ovarian insufficiency due to gonadal dysgenesis may benefit from hormone replacement therapy to prevent osteoporosis. For secondary amenorrhoea, it is important to exclude pregnancy, lactation, and menopause in women 40 years of age or older and treat the underlying cause accordingly. It is important to note that hypothyroidism may also cause amenorrhoea.

The Pearl Index is frequently utilized to measure the effectiveness of a contraception method. It indicates the number of pregnancies that would occur if one hundred women used the contraceptive method for one year. Therefore, if the Pearl Index is 0.2 and the medication is used perfectly, we can expect to see 0.2 pregnancies for every hundred women using the pill for one year – or 2 for every thousand.

Understanding Contraception: A Basic Overview

Contraception has come a long way in the past 50 years, with the development of effective methods being one of the most significant advancements in medicine. There are various types of contraception available, including barrier methods, daily methods, and long-acting methods of reversible contraception (LARCs).

Barrier methods, such as condoms, physically block sperm from reaching the egg. While they can help protect against sexually transmitted infections (STIs), their success rate is relatively low, particularly when used by young people.

Daily methods include the combined oral contraceptive pill, which inhibits ovulation, and the progesterone-only pill, which thickens cervical mucous. However, the combined pill increases the risk of venous thromboembolism and breast and cervical cancer.

LARCs include implantable contraceptives and injectable contraceptives, which both inhibit ovulation and thicken cervical mucous. The implantable contraceptive lasts for three years, while the injectable contraceptive lasts for 12 weeks. The intrauterine system (IUS) and intrauterine device (IUD) are also LARCs, with the IUS preventing endometrial proliferation and thickening cervical mucous, and the IUD decreasing sperm motility and survival.

It is important to note that each method of contraception has its own set of benefits and risks, and it is essential to consult with a healthcare provider to determine the best option for individual needs and circumstances.

The UK Government implemented legal modifications in October 2015 regarding the response of doctors in England and Wales to instances of female genital mutilation (FGM). As per the guidelines of the General Medical Council (GMC), doctors are required to report all cases of FGM in individuals under the age of 18 to the police. This can be done by contacting 101 or using the established local channels. Reporting is compulsory to align with our responsibilities towards child protection and safeguarding.

Understanding Female Genital Mutilation

Female genital mutilation (FGM) is a term used to describe any procedure that involves the partial or complete removal of the external female genitalia or any other injury to the female genital organs for non-medical reasons. The World Health Organization (WHO) has classified FGM into four types. Type 1 involves the partial or total removal of the clitoris and/or the prepuce, while type 2 involves the partial or total removal of the clitoris and the labia minora, with or without excision of the labia majora. Type 3 involves the narrowing of the vaginal orifice with the creation of a covering seal by cutting and appositioning the labia minora and/or the labia majora, with or without excision of the clitoris. Finally, type 4 includes all other harmful procedures to the female genitalia for non-medical purposes, such as pricking, piercing, incising, scraping, and cauterization. It is important to understand the different types of FGM to raise awareness and prevent this harmful practice.

Tumour Markers for Different Types of Cancer

Tumour markers are substances that are produced by cancer cells or by the body in response to cancer. They can be detected in blood, urine, or tissue samples and can help in the diagnosis, monitoring, and treatment of cancer. Here are some tumour markers for different types of cancer:

– Ovarian cancer: CA125 is highly suggestive of ovarian cancer.
– Colorectal cancer: CEA is a tumour marker for bowel cancer.
– Breast cancer: CA 15–3 is a tumour marker for breast cancer.
– Pancreatic cancer: CA19–9 is a tumour marker for pancreatic cancer.
– Rectal cancer: Unfortunately, there is no specific marker for rectal cancer.

It is important to note that tumour markers are not always reliable and can be elevated in non-cancerous conditions as well. Therefore, they should be used in conjunction with other diagnostic tests and clinical evaluations.

Common Causes of Abnormal Uterine Bleeding in Women

Abnormal uterine bleeding is a common gynecological problem that can have various underlying causes. Here are some of the most common causes of abnormal uterine bleeding in women:

Endometriosis: This condition occurs when the endometrial tissue grows outside the uterus, usually in the ovaries or pelvic cavity. Symptoms include painful periods, painful intercourse, painful bowel movements, and adnexal tenderness. Endometriosis can also lead to infertility.

Ovulatory dysfunctional uterine bleeding: This condition is caused by excessive production of vasoconstrictive prostaglandins in the endometrium during a menstrual period. Symptoms include heavy and painful periods. Non-steroidal anti-inflammatory drugs are the treatment of choice.

Cervical cancer: This type of cancer is associated with human papillomavirus infection, smoking, early intercourse, multiple sexual partners, use of oral contraceptives, and immunosuppression. Symptoms include vaginal spotting, post-coital bleeding, dyspareunia, and vaginal discharge. Cervical cancer is rare before the age of 25 and is unlikely to cause dysmenorrhea, dyspareunia, dyschezia, or adnexal tenderness.

Submucosal leiomyoma: This is a benign neoplastic mass of myometrial origin that protrudes into the intrauterine cavity. Symptoms include heavy and painful periods, but acute pain is rare.

Endometrial polyps: These are masses of endometrial tissue attached to the inner surface of the uterus. They are more common around menopausal age and can cause heavy or irregular bleeding. They are usually not associated with pain or menstrual cramps and are not pre-malignant.

Understanding the Common Causes of Abnormal Uterine Bleeding in Women

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

Investigating Postcoital Bleeding: The Role of Speculum Examination and Other Tests

Postcoital bleeding can be caused by various abnormalities of the cervix, including cervical ectropion, polyps, infection, or cervical cancer. In women presenting with postcoital bleeding, cervical cancer should be suspected if there are other symptoms such as vaginal discharge, pelvic pain, or dyspareunia. Risk factors for cervical cancer include smoking, oral contraceptive use, HPV infection, HIV infection, immunosuppression, and family history.

The primary screening tool for cervical cancer is a cervical smear, which should be done every three years for women aged 25-49. If a patient presents with postcoital bleeding, the first step is to perform a speculum examination to visualize the cervix, which can detect over 80% of cervical cancers. If the cervix appears normal, a smear may be taken if it is due, and swabs can be taken for STI testing and pregnancy testing. If symptoms persist, referral to colposcopy may be necessary.

Other tests such as blood tests, urine dipstick, and high vaginal swab may be useful in certain cases, but they are not the primary investigation for postcoital bleeding. Blood tests may be indicated later, while urine dipstick and high vaginal swab are secondary investigations following visualisation of the cervix.

In summary, speculum examination is the key initial investigation for postcoital bleeding, and cervical smear is the primary screening tool for cervical cancer. Other tests may be useful in specific situations, but they should not replace the essential role of speculum examination and cervical smear in the evaluation of postcoital bleeding.

If one COCP pill is missed, the individual should take the missed pill as soon as possible, but no further action is necessary. They should also take the next pill at the usual time, even if that means taking two pills in one day. Emergency contraception is not required in this situation, as only one pill was missed. However, if two or more pills are missed in week 3 of a packet, it is recommended to omit the pill-free interval and use barrier contraception for 7 days.

Missed Pills in Combined Oral Contraceptive Pill

When taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol, it is important to know what to do if a pill is missed. The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their recommendations in recent years. If one pill is missed at any time in the cycle, the woman should take the last pill even if it means taking two pills in one day and then continue taking pills daily, one each day. No additional contraceptive protection is needed in this case.

However, if two or more pills are missed, the woman should take the last pill even if it means taking two pills in one day, leave any earlier missed pills, and then continue taking pills daily, one each day. In this case, the woman should use condoms or abstain from sex until she has taken pills for 7 days in a row. If pills are missed in week 1 (Days 1-7), emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week 1. If pills are missed in week 2 (Days 8-14), after seven consecutive days of taking the COC there is no need for emergency contraception.

If pills are missed in week 3 (Days 15-21), the woman should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of 7 days on, 7 days off. It is important to follow these guidelines to ensure the effectiveness of the COC in preventing pregnancy.

When a woman experiences postmenopausal bleeding (PMB), the primary concern is the possibility of endometrial cancer. This is because endometrial adenocarcinoma is strongly linked to PMB and early detection is crucial for better prognosis. The patient in this scenario has two risk factors for endometrial adenocarcinoma – obesity and hypertension. Other risk factors include high levels of oestrogen, late menopause, polycystic ovarian syndrome, diabetes mellitus, and tamoxifen use.

Endometrial cancer is a type of cancer that is commonly found in women who have gone through menopause, but it can also occur in around 25% of cases before menopause. The prognosis for this type of cancer is usually good due to early detection. There are several risk factors associated with endometrial cancer, including obesity, nulliparity, early menarche, late menopause, unopposed estrogen, diabetes mellitus, tamoxifen, polycystic ovarian syndrome, and hereditary non-polyposis colorectal carcinoma. Postmenopausal bleeding is the most common symptom of endometrial cancer, which is usually slight and intermittent initially before becoming more heavy. Pain is not common and typically signifies extensive disease, while vaginal discharge is unusual.

When investigating endometrial cancer, women who are 55 years or older and present with postmenopausal bleeding should be referred using the suspected cancer pathway. The first-line investigation is trans-vaginal ultrasound, which has a high negative predictive value for a normal endometrial thickness (< 4 mm). Hysteroscopy with endometrial biopsy is also commonly used for investigation. The management of localized disease involves total abdominal hysterectomy with bilateral salpingo-oophorectomy, while patients with high-risk disease may have postoperative radiotherapy. progesterone therapy is sometimes used in frail elderly women who are not considered suitable for surgery. It is important to note that the combined oral contraceptive pill and smoking are protective against endometrial cancer.

During pregnancy, uterine fibroids may experience growth. These fibroids are common and often do not show any symptoms. However, in non-pregnant women, they can cause menorrhagia. In early pregnancy, they grow due to oestrogen and can cause pelvic pain and pressure. If they grow too quickly and surpass their blood supply, they may undergo ‘red degeneration’. This patient’s symptoms, including pelvic pain and a history of menorrhagia, suggest that the growth of pre-existing fibroids due to oestrogen may be the cause. However, further investigation with ultrasound is necessary to confirm this diagnosis. Ectopic pregnancies are rare in the second trimester and are typically detected during routine ultrasound scans. This patient is unlikely to have an ectopic pregnancy as her first ultrasound scan would have confirmed an intrauterine pregnancy. Pelvic inflammatory disease is not the most likely cause of this patient’s symptoms as it is associated with additional symptoms such as vaginal discharge and dysuria, and the patient would likely be febrile. The growth of pre-existing fibroids due to decreased progesterone is incorrect as progesterone, like oestrogen, is increased during pregnancy. This patient does not exhibit symptoms of dysuria, renal angle tenderness, or pyrexia.

Understanding Fibroid Degeneration

Uterine fibroids are non-cancerous growths that can develop in the uterus. They are sensitive to oestrogen and can grow during pregnancy. However, if the growth of the fibroids exceeds their blood supply, they can undergo a type of degeneration known as red or ‘carneous’ degeneration. This condition is characterized by symptoms such as low-grade fever, pain, and vomiting.

Fortunately, fibroid degeneration can be managed conservatively with rest and analgesia. With proper care, the symptoms should resolve within 4-7 days.

There are many options available for contraception, each with their own advantages and disadvantages. It is important to discuss these options to find the best fit for the patient. In this case, the progesterone only contraceptive pill is the most appropriate option due to the patient’s history of migraine with aura and heavy menstrual cycle. The combined oral contraceptive pill is not recommended for this patient. The intrauterine system is a popular option for menorrhagia, but the patient does not want an invasive device. The contraceptive implant is also invasive and not preferred by the patient. Condoms are a good barrier method, but the POCP will also help with the patient’s heavy and irregular periods.

When experiencing atrophic vaginitis, the dryness of the vaginal mucosa can cause pain, itching, and dyspareunia. The first-line treatment for this condition is topical oestrogen cream, which helps to restore the vaginal mucosa. However, lubricants and moisturisers can also provide short-term relief while waiting for the topical oestrogen cream to take effect. Oestrogen secreting pessaries are an alternative to topical oestrogen cream, but using them together would result in an excessive dose of oestrogen. Sitz baths are useful for irritation and itching of the perineum, but they do not address internal vaginal symptoms. Warm or cold compresses may provide temporary relief, but they are not a long-term solution.

Atrophic vaginitis is a condition that commonly affects women who have gone through menopause. Its symptoms include vaginal dryness, pain during sexual intercourse, and occasional spotting. Upon examination, the vagina may appear dry and pale. The recommended treatment for this condition is the use of vaginal lubricants and moisturizers. If these do not provide relief, a topical estrogen cream may be prescribed.

Ovarian cancer typically spreads initially through local invasion, rather than through the lymphatic or hematological routes. This patient’s symptoms, including IBS-like symptoms, irregular vaginal bleeding, and a raised CA125, suggest ovarian cancer. The stages of ovarian cancer range from confined to the ovaries (Stage 1) to spread beyond the pelvis to the abdomen (Stage 3), with local spread within the pelvis (Stage 2) in between. While lymphatic and hematological routes can also be involved in the spread of ovarian cancer, they tend to occur later than local invasion within the pelvis. The para-aortic lymph nodes are a common site for lymphatic spread, while the liver is a common site for hematological spread.

Ovarian cancer is a common malignancy in women, ranking fifth in frequency. It is most commonly diagnosed in women over the age of 60 and has a poor prognosis due to late detection. The majority of ovarian cancers, around 90%, are of epithelial origin, with serous carcinomas accounting for 70-80% of cases. Interestingly, recent research suggests that many ovarian cancers may actually originate in the distal end of the fallopian tube. Risk factors for ovarian cancer include a family history of BRCA1 or BRCA2 gene mutations, early menarche, late menopause, and nulliparity.

Clinical features of ovarian cancer are often vague and can include abdominal distension and bloating, abdominal and pelvic pain, urinary symptoms such as urgency, early satiety, and diarrhea. The initial diagnostic test recommended by NICE is a CA125 blood test, although this can also be elevated in other conditions such as endometriosis and benign ovarian cysts. If the CA125 level is raised, an urgent ultrasound scan of the abdomen and pelvis should be ordered. However, a CA125 test should not be used for screening asymptomatic women. Diagnosis of ovarian cancer is difficult and usually requires a diagnostic laparotomy.

Management of ovarian cancer typically involves a combination of surgery and platinum-based chemotherapy. Unfortunately, 80% of women have advanced disease at the time of diagnosis, leading to a 5-year survival rate of only 46%. It was previously thought that infertility treatment increased the risk of ovarian cancer due to increased ovulation, but recent evidence suggests that this is not a significant factor. In fact, the combined oral contraceptive pill and multiple pregnancies have been shown to reduce the risk of ovarian cancer by reducing the number of ovulations.

The appropriate option for emergency contraception in this case is ulipristal, which can be prescribed up to 120 hours after unprotected sexual intercourse. Levonorgestrel, which must be taken within 72 hours, is not a suitable option. Insertion of an intrauterine device or system is also inappropriate as the patient declined invasive contraception. Mifepristone is not licensed for emergency contraception.

Emergency contraception is available in the UK through two methods: emergency hormonal contraception and intrauterine device (IUD). Emergency hormonal contraception includes two types of pills: levonorgestrel and ulipristal. Levonorgestrel works by stopping ovulation and inhibiting implantation, while ulipristal primarily inhibits ovulation. Levonorgestrel should be taken as soon as possible after unprotected sexual intercourse, within 72 hours, and is 84% effective when used within this time frame. The dose should be doubled for those with a BMI over 26 or weight over 70kg. Ulipristal should be taken within 120 hours of intercourse and may reduce the effectiveness of hormonal contraception. The most effective method of emergency contraception is the copper IUD, which can be inserted within 5 days of unprotected intercourse or up to 5 days after the likely ovulation date. It may inhibit fertilization or implantation and is 99% effective regardless of where it is used in the cycle. Prophylactic antibiotics may be given if the patient is at high risk of sexually transmitted infection.

Adverse Effects of Hormone Replacement Therapy

Hormone replacement therapy (HRT) is a treatment that involves the use of a small dose of oestrogen, often combined with a progesterone in women with a uterus, to alleviate menopausal symptoms. While it can be effective in reducing symptoms such as hot flashes and vaginal dryness, HRT can also have adverse effects and potential complications.

Some common side-effects of HRT include nausea, breast tenderness, fluid retention, and weight gain. However, there are also more serious potential complications associated with HRT. For example, the use of HRT has been linked to an increased risk of breast cancer, particularly when a progesterone is added. The Women’s Health Initiative study found a relative risk of 1.26 at 5 years of developing breast cancer with HRT use. The risk of breast cancer is also related to the duration of use, and it begins to decline when HRT is stopped.

Another potential complication of HRT is an increased risk of endometrial cancer. Oestrogen by itself should not be given as HRT to women with a womb, as this can increase the risk of endometrial cancer. The addition of a progesterone can reduce this risk, but it is not eliminated completely. The British National Formulary states that the additional risk is eliminated if a progesterone is given continuously.

HRT has also been associated with an increased risk of venous thromboembolism (VTE), particularly when a progesterone is added. However, transdermal HRT does not appear to increase the risk of VTE. Women who are at high risk for VTE should be referred to haematology before starting any treatment, even transdermal, according to the National Institute for Health and Care Excellence (NICE).

Finally, HRT has been linked to an increased risk of stroke and ischaemic heart disease if taken more than 10 years after menopause. It is important for women considering HRT to discuss the potential risks and benefits with their healthcare provider and make an informed decision based on their individual circumstances.

Causes and Precipitants of Urge Incontinence: A Brief Overview

Urge incontinence, characterized by involuntary leakage of urine associated with or following urgency, is a common condition in women. It is caused by overactivity of the detrusor muscle in the bladder wall, leading to irregular contractions during the filling phase and subsequent leakage of urine. While there are many causes and precipitants of urge incontinence, it is often difficult to identify a single factor in the presence of multiple contributing factors.

Some of the common causes of urge incontinence include poorly controlled diabetes, excess caffeine and alcohol intake, neurological dysfunction, urinary infection or faecal impaction, and adverse medication effects. In the case of a patient presenting with a short history of symptoms, urinary tract infection is the most likely cause, and prompt treatment is necessary to prevent complications.

It is important to rule out developing cauda equina, a medical emergency that can lead to paralysis, in patients presenting with short-term urinary incontinence. Normal anal tone and perineal sensation can help exclude this condition.

Excess alcohol and caffeine intake can precipitate symptoms of urge incontinence by inducing diuresis, causing frequency and polyuria. Chronic constipation, particularly in patients with diverticular disease, can also compress the bladder and lead to urge incontinence symptoms. Systemic illnesses such as diabetes mellitus can cause glycosuria and polyuria, leading to bladder irritation and detrusor instability. Finally, oestrogen deficiency associated with postmenopausal status can cause vaginitis and urethritis, both of which can precipitate urge incontinence symptoms.

In conclusion, urge incontinence is a complex condition with multiple contributing factors. Identifying and addressing these factors can help manage symptoms and improve quality of life for affected patients.

Depo-provera is linked to an increase in weight.

If this woman is concerned about weight gain, it is best to avoid depo-provera, which is the primary injectable contraceptive in the UK. Depo-provera can cause various adverse effects, including weight gain, irregular bleeding, delayed return to fertility, and an increased risk of osteoporosis.

While some users of the combined oral contraceptive pill have reported weight gain, a Cochrane review does not support a causal relationship. There are no reasons for this woman to avoid the combined oral contraceptive pill.

The progesterone-only pill has not been associated with weight gain and is safe for use in this woman.

The intra-uterine system (IUS) does not cause weight gain in users and is a viable option for this woman.

The subdermal contraceptive implant can cause irregular or heavy bleeding, as well as progesterone-related side effects such as headaches, nausea, and breast pain. However, it is not typically associated with weight gain and is not contraindicated for use in this situation.

Injectable Contraceptives: Depo Provera

Injectable contraceptives are a popular form of birth control in the UK, with Depo Provera being the main option available. This contraceptive contains 150 mg of medroxyprogesterone acetate and is administered via intramuscular injection every 12 weeks. It can be given up to 14 weeks after the last dose without the need for extra precautions. The primary method of action is by inhibiting ovulation, while secondary effects include cervical mucous thickening and endometrial thinning.

However, there are some disadvantages to using Depo Provera. Once the injection is given, it cannot be reversed, and there may be a delayed return to fertility of up to 12 months. Adverse effects may include irregular bleeding and weight gain, and there is a potential increased risk of osteoporosis. It should only be used in adolescents if no other method of contraception is suitable.

It is important to note that there are contraindications to using Depo Provera, such as current breast cancer (UKMEC 4) or past breast cancer (UKMEC 3). While Noristerat is another injectable contraceptive licensed in the UK, it is rarely used in clinical practice and is given every 8 weeks. Overall, injectable contraceptives can be an effective form of birth control, but it is important to weigh the potential risks and benefits before deciding on this method.

Contraception for Women with Epilepsy

Women with epilepsy need to consider several factors when choosing a contraceptive method. Firstly, they need to consider how the contraceptive may affect the effectiveness of their anti-epileptic medication. Secondly, they need to consider how their anti-epileptic medication may affect the effectiveness of the contraceptive. Lastly, they need to consider the potential teratogenic effects of their anti-epileptic medication if they become pregnant.

To address these concerns, the Faculty of Sexual & Reproductive Healthcare (FSRH) recommends that women with epilepsy consistently use condoms in addition to other forms of contraception. For women taking certain anti-epileptic medications such as phenytoin, carbamazepine, barbiturates, primidone, topiramate, and oxcarbazepine, the FSRH recommends the use of the COCP and POP as UKMEC 3, the implant as UKMEC 2, and the Depo-Provera, IUD, and IUS as UKMEC 1.

For women taking lamotrigine, the FSRH recommends the use of the COCP as UKMEC 3 and the POP, implant, Depo-Provera, IUD, and IUS as UKMEC 1. If a COCP is chosen, it should contain a minimum of 30 µg of ethinylestradiol. By considering these recommendations, women with epilepsy can make informed decisions about their contraceptive options and ensure the safety and effectiveness of their chosen method.

Understanding Vaginal Discharge: Common Causes and Key Features

Vaginal discharge is a common symptom experienced by many women, but it is not always a sign of a pathological condition. There are various causes of vaginal discharge, including physiological factors and infections. Some of the common causes of vaginal discharge include Candida, Trichomonas vaginalis, and bacterial vaginosis. However, less common causes such as gonorrhea, chlamydia, ectropion, foreign body, and cervical cancer can also lead to vaginal discharge.

It is important to note that the key features of each cause of vaginal discharge can vary. For instance, Candida infection may present with a discharge that resembles cottage cheese, accompanied by vulvitis and itch. On the other hand, Trichomonas vaginalis infection may cause an offensive, yellow/green, frothy discharge, along with vulvovaginitis and a strawberry cervix. Bacterial vaginosis, another common cause of vaginal discharge, may present with an offensive, thin, white/grey, ‘fishy’ discharge.

MRI is the most effective imaging technique for diagnosing adenomyosis, which is the presence of endometrial tissue in the myometrium. While ultrasound can also aid in diagnosis, it is not as reliable as MRI. Laparoscopy is used to diagnose endometriosis, but it cannot detect adenomyosis as it occurs within the uterine wall. CT is not a suitable imaging technique for adenomyosis as it cannot differentiate between different types of tissue. Hysterosalpingography is used for imaging the uterine lining and fallopian tubes, typically during fertility treatment, but it cannot provide an image of the myometrium.

Understanding Adenomyosis

Adenomyosis is a medical condition that occurs when endometrial tissue grows within the muscular walls of the uterus. This condition is more common in women who have had multiple pregnancies and are nearing the end of their reproductive years. Symptoms of adenomyosis include painful menstrual cramps, heavy menstrual bleeding, and an enlarged and tender uterus.

To diagnose adenomyosis, doctors typically use magnetic resonance imaging (MRI) as it is the most effective method. Treatment options for adenomyosis include managing symptoms with pain relief medication, using tranexamic acid to control heavy bleeding, and administering gonadotropin-releasing hormone (GnRH) agonists to reduce estrogen levels. In severe cases, uterine artery embolization or hysterectomy may be necessary. Hysterectomy is considered the definitive treatment for adenomyosis.

In summary, adenomyosis is a condition that affects the uterus and can cause painful menstrual cramps, heavy bleeding, and an enlarged uterus. It is more common in women who have had multiple pregnancies and are nearing the end of their reproductive years. Diagnosis is typically done through MRI, and treatment options include managing symptoms, medication, and surgery.

Premenstrual syndrome (PMS) can be helped by SSRIs, either continuously or during the luteal phase. If a patient’s symptoms are significantly impacting their day-to-day life and have not improved with first-line treatment using a combined oral contraceptive pill, antidepressant treatment with SSRIs is recommended. Co-cyprindiol, levonorgestrel-releasing intrauterine systems, mirtazapine, and the copper coil are not indicated for the management of PMS.

Understanding Premenstrual Syndrome (PMS)

Premenstrual syndrome (PMS) is a condition that affects women during the luteal phase of their menstrual cycle. It is characterized by emotional and physical symptoms that can range from mild to severe. PMS only occurs in women who have ovulatory menstrual cycles and does not occur before puberty, during pregnancy, or after menopause.

Emotional symptoms of PMS include anxiety, stress, fatigue, and mood swings. Physical symptoms may include bloating and breast pain. The severity of symptoms varies from woman to woman, and management options depend on the severity of symptoms.

Mild symptoms can be managed with lifestyle advice, such as getting enough sleep, exercising regularly, and avoiding smoking and alcohol. Specific advice includes eating regular, frequent, small, balanced meals that are rich in complex carbohydrates.

Moderate symptoms may benefit from a new-generation combined oral contraceptive pill (COCP), such as Yasmin® (drospirenone 3 mg and ethinylestradiol 0.030 mg). Severe symptoms may benefit from a selective serotonin reuptake inhibitor (SSRI), which can be taken continuously or just during the luteal phase of the menstrual cycle (for example, days 15-28, depending on the length of the cycle). Understanding PMS and its management options can help women better cope with this common condition.

Treatment Options for Infertility in Women with PCOS

Polycystic ovary syndrome (PCOS) is a common cause of infertility in women. Clomiphene citrate is the first-line medication used to induce ovulation in women with PCOS who wish to conceive. It works by binding to hypothalamic estrogen receptors, inhibiting the negative feedback on follicle-stimulating hormone (FSH) and triggering ovulation. However, it is important to counsel women about the increased risk of multiple pregnancy when treated with Clomiphene. Metformin, once considered a viable option for PCOS-related infertility, is now considered inferior to Clomiphene. However, it can be used in combination with Clomiphene to increase the success of ovulation induction. Gonadotrophins are recommended as second-line treatment for women who do not respond to Clomiphene. Laparoscopic ovarian drilling is a surgical option reserved for cases where Clomiphene has failed. It involves destroying ovarian stroma to reduce androgen-secreting tissue and induce ovulation. The choice of treatment depends on individual patient factors and should be discussed with a healthcare provider.

A high vaginal swab is not necessary for diagnosing vaginal candidiasis if the symptoms strongly suggest its presence. Symptoms such as genital itching and white discharge are indicative of Candida albicans infection. The discharge appears like cottage cheese and causes inflammation and itching, but the vaginal pH remains normal (around 4.0-4.5 in women of reproductive age). Since vaginal candidiasis is a common condition, a confident clinical suspicion based on the examination can be enough to diagnose and initiate treatment.

The other options for diagnosis are incorrect. Gardnerella vaginalis is a normal part of the vaginal flora, but it’s overgrowth can lead to bacterial vaginosis. Unlike vaginal candidiasis, bacterial vaginosis presents with thinner white discharge and a fishy odor that intensifies with the addition of potassium hydroxide. Additionally, the vaginal pH would be elevated (> 4.5).

Vaginal candidiasis, also known as thrush, is a common condition that many women can diagnose and treat themselves. Candida albicans is responsible for about 80% of cases, while other candida species cause the remaining 20%. Although most women have no predisposing factors, certain factors such as diabetes mellitus, antibiotics, steroids, pregnancy, and HIV can increase the likelihood of developing vaginal candidiasis. Symptoms include non-offensive discharge resembling cottage cheese, vulvitis, itching, vulval erythema, fissuring, and satellite lesions. A high vaginal swab is not routinely indicated if the clinical features are consistent with candidiasis. Treatment options include local or oral therapy, with oral fluconazole 150 mg as a single dose being the first-line treatment according to NICE Clinical Knowledge Summaries. If there are vulval symptoms, a topical imidazole may be added to an oral or intravaginal antifungal. Pregnant women should only use local treatments. Recurrent vaginal candidiasis is defined as four or more episodes per year by BASHH. Compliance with previous treatment should be checked, and a high vaginal swab for microscopy and culture should be performed to confirm the diagnosis. A blood glucose test may be necessary to exclude diabetes, and differential diagnoses such as lichen sclerosus should be ruled out. An induction-maintenance regime involving oral fluconazole may be considered. Induction involves taking oral fluconazole every three days for three doses, while maintenance involves taking oral fluconazole weekly for six months.

Possible Causes of Sudden Pelvic Pain: A Differential Diagnosis

Sudden pelvic pain can be a sign of various medical conditions. In this case, the patient’s symptoms suggest ovarian torsion, a condition that occurs when the ovary twists on its blood supply, causing ischemia and infarction. The resulting pain is severe, sharp, and sudden, often accompanied by tenderness and internal bleeding. However, other possible causes of sudden pelvic pain should also be considered.

Rectal diseases or trauma are unlikely to explain the patient’s current presentation. Similarly, while appendicitis can cause abdominal pain, fever, nausea, and anorexia, the pattern of pain is different, starting as dull pain around the belly button and becoming sharp and localized to the right lower quadrant over time. Rovsing’s sign, which is pain in the right lower quadrant when pressure is applied to the left lower quadrant, is often positive in appendicitis.

A ureteral stone can also cause sudden-onset pelvic and flank pain, but it is not associated with pelvic bleeding. Urinary tract stones typically cause colicky pain, which comes and goes in waves, rather than the unrelenting pain described by the patient.

Finally, a ruptured Fallopian tube can be a complication of an ectopic pregnancy, but the patient’s recent normal menstrual periods make this diagnosis less likely. In ectopic tubal pregnancy, the patient usually complains of amenorrhea, abnormal uterine bleeding, and pelvic pain of several days to weeks’ duration.

In summary, while ovarian torsion is a possible cause of the patient’s sudden pelvic pain, other conditions should also be considered and ruled out through further evaluation and testing.

If a woman misses 2 pills in week 3 of taking the COCP, she should finish the remaining pills in the current pack and start a new pack immediately without taking the pill-free interval. Missing 2 pills means that it has been 72 hours since the last pill was taken, and the standard rule is to take 2 pills on the same day and continue taking one pill each day until the end of the pack. It is important not to take more than 2 pills in one day, and emergency contraception is only necessary if more than 7 consecutive pills are missed. In this case, the woman has not taken the required 7 consecutive pills to be protected during the pill-free interval, so she should start the new pack immediately. However, the chances of pregnancy are low if she has taken 7 pills consecutively the prior week.

Missed Pills in Combined Oral Contraceptive Pill

When taking a combined oral contraceptive (COC) pill containing 30-35 micrograms of ethinylestradiol, it is important to know what to do if a pill is missed. The Faculty of Sexual and Reproductive Healthcare (FSRH) has updated their recommendations in recent years. If one pill is missed at any time in the cycle, the woman should take the last pill even if it means taking two pills in one day and then continue taking pills daily, one each day. No additional contraceptive protection is needed in this case.

However, if two or more pills are missed, the woman should take the last pill even if it means taking two pills in one day, leave any earlier missed pills, and then continue taking pills daily, one each day. In this case, the woman should use condoms or abstain from sex until she has taken pills for 7 days in a row. If pills are missed in week 1 (Days 1-7), emergency contraception should be considered if she had unprotected sex in the pill-free interval or in week 1. If pills are missed in week 2 (Days 8-14), after seven consecutive days of taking the COC there is no need for emergency contraception.

If pills are missed in week 3 (Days 15-21), the woman should finish the pills in her current pack and start a new pack the next day, thus omitting the pill-free interval. Theoretically, women would be protected if they took the COC in a pattern of 7 days on, 7 days off. It is important to follow these guidelines to ensure the effectiveness of the COC in preventing pregnancy.

Understanding Mittelschmerz: Mid-Cycle Pain in Women

Mittelschmerz, which translates to middle pain in German, is a common experience for approximately 20% of women during mid-cycle. This pain or discomfort occurs when the membrane covering the ovary stretches to release the egg, resulting in pressure and pain. While the amount of pain varies from person to person, some may experience intense pain that can last for days. In severe cases, the pain may be mistaken for appendicitis.

However, other conditions such as acute appendicitis, ruptured ectopic pregnancy, incarcerated hernia, and pelvic inflammatory disease should also be considered and ruled out through physical examination and investigations. It is important to note that a ruptured ectopic pregnancy is a medical emergency and can present with profuse internal bleeding and hypovolaemic shock.

In this case, the patient’s physical examination and investigations suggest recent ovulation and fluid in the pouch of Douglas, making Mittelschmerz the most likely diagnosis. It is important for women to understand and recognize this common experience to differentiate it from other potential conditions.

The contraceptive implant primarily works by inhibiting ovulation through the slow release of progesterone hormone. While it also increases cervical mucous thickness, this is not its main mode of action. The progesterone-only pill also increases cervical mucous thickness, while the intrauterine copper device decreases sperm viability. The intrauterine system prevents implantation of the ovum by exerting local progesterone onto the uterine lining.

Understanding the Mode of Action of Contraceptives

Contraceptives are used to prevent unwanted pregnancies. They work by different mechanisms depending on the type of contraceptive used. The Faculty for Sexual and Reproductive Health (FSRH) has provided a table that outlines the mode of action of standard contraceptives and emergency contraception.

Standard contraceptives include the combined oral contraceptive pill, progesterone-only pill, injectable contraceptive, implantable contraceptive, and intrauterine contraceptive device/system. The combined oral contraceptive pill and injectable/implantable contraceptives primarily work by inhibiting ovulation, while the progesterone-only pill and some injectable/implantable contraceptives thicken cervical mucous to prevent sperm from reaching the egg. The intrauterine contraceptive device/system decreases sperm motility and survival and prevents endometrial proliferation.

Emergency contraception, which is used after unprotected sex or contraceptive failure, also works by different mechanisms. Levonorgestrel and ulipristal inhibit ovulation, while the intrauterine contraceptive device is toxic to sperm and ovum and inhibits implantation.

Understanding the mode of action of contraceptives is important in choosing the most appropriate method for an individual’s needs and preferences. It is also important to note that no contraceptive method is 100% effective, and the use of condoms can provide additional protection against sexually transmitted infections.

If a cervical smear is inadequate, it is recommended to repeat the test within 3 months. This is the correct course of action for the patient in question, as her routine smear was deemed inadequate. Referral for colposcopy is not necessary at this stage, as it is only indicated if there are two consecutive inadequate smears that are 3 months apart. Waiting for 3 years to repeat the smear would not be appropriate, as this is the interval for routine recall for a patient of her age. Similarly, waiting for 6 or 12 months to repeat the smear would not be appropriate, as these timeframes are only indicated for specific circumstances such as testing for cure following treatment or if the most recent smear was hrHPV positive without cytological abnormalities.

The cervical cancer screening program has evolved to include HPV testing, which allows for further risk stratification. A negative hrHPV result means a return to normal recall, while a positive result requires cytological examination. Abnormal cytology results lead to colposcopy, while normal cytology results require a repeat test at 12 months. Inadequate samples require a repeat within 3 months, and two consecutive inadequate samples lead to colposcopy. Treatment for CIN typically involves LLETZ or cryotherapy. Individuals who have been treated for CIN should be invited for a test of cure repeat cervical sample 6 months after treatment.

Management Options for Endometriosis-Related Pain: A Guide for Healthcare Professionals

Endometriosis is a condition where endometrial tissue grows outside the uterus, causing pain and discomfort. Hormonal contraception is an effective treatment option for women who do not wish to conceive. The combined oral contraceptive pill suppresses ovarian function and limits the effect of estrogen on endometrial tissue. progesterone-containing contraceptives cause atrophy of the endometrial tissue. A trial of three months is recommended before reassessment.

Hysterectomy is indicated for adenomyosis or heavy menstrual bleeding that has not resolved with other treatments. A hysteroscopy is not necessary for a newly diagnosed young patient. A trial of ibuprofen or combination therapy is the first step in pain management, but NSAIDs are contraindicated for asthmatic patients who have already tried paracetamol.

Further laparoscopy for excision and/or ablation of endometriotic deposits is indicated if there is further disease. However, if all visible deposits were removed during diagnostic laparoscopy, a further laparoscopy is not necessary at present.

Ovarian cystectomy is recommended for women with endometriotic cysts who are concerned about fertility. Laparoscopic removal of the cyst wall can improve the chances of spontaneous pregnancy and reduce the risk of recurrence of endometriomas. These guidelines are based on NICE recommendations.